department of pharmacology



Robert A. Copeland, Ph.D.

Vice President
Enzymology & Mechanistic Pharmacology GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceutical Company

Robert A. Copeland, Ph.D. is Vice President, Enzymology & Mechanistic Pharmacology at GlaxoSmithKline Pharmaceutical Company, where he supports efforts in oncology, infectious, cardiovascular and urogenital diseases. He is also Adjunct Professor of Biochemistry and Biophysics and a Fellow of the Eldridge Reeves Johnson Foundation at the Univ. of Pennsylvania School of Medicine.

He received his doctorate in chemistry from Princeton Univ. and went on to do postdoctoral studies at the California Institute of Technology. Before joining GSK he held scientific staff positions at Merck Research Laboratories, DuPont Merck and Bristol-Myers Squibb and a faculty position at the University of Chicago, Prizker School of Medicine. Dr. Copeland’s
research interest is in elucidating the determinants of drug recognition by their biological targets, and the use of this information in the discovery and design of new medicines.

He has made significant contributions to drug discovery projects across a wide range of therapeutic areas, and has received numerous awards for his research accomplishments. His awards include a Synthex Scholars Award for excellence in cardiovascular research and an Established Investigatorship from the American Heart Association. Dr. Copeland has published
over 130 papers and reviews in scientific journals and has authored 4 books in the areas of protein biochemistry and enzymology. His latest book, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists published in March 2005.